Smith TJ. Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy. Thyroid. 2025. https://doi.org/10.1089/thy.2024.0606.

Article  PubMed  Google Scholar 

Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013. https://doi.org/10.1210/jc.2012-3873.

Article  PubMed  Google Scholar 

Kahaly GJ, Grebe SKG, Lupo MA, et al. Graves’ disease: diagnostic and therapeutic challenges (multimedia activity). Am J Med. 2011;124:S2-3. https://doi.org/10.1016/J.AMJMED.2011.03.001.

Article  PubMed  CAS  Google Scholar 

Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142:147. https://doi.org/10.1016/J.AJO.2006.02.047.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–38. https://doi.org/10.1056/NEJMra0905750.Graves.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cockerham KP, Padnick-Silver L, Stuertz N, et al. Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther. 2021;10:975–87. https://doi.org/10.1007/S40123-021-00385-8.

Article  PubMed  PubMed Central  Google Scholar 

Ponto KA, Pitz S, Pfeiffer N, et al. Quality of life and occupational disability in endocrine orbitopathy. Deutsches Aerzteblatt. 2009. https://doi.org/10.3238/arztebl.2009.0283.

Article  Google Scholar 

Ferløv-Schwensen C, Brix TH, Hegedüs L. Death by suicide in Graves’ disease and Graves’ orbitopathy: a nationwide Danish Register study. Thyroid. 2017;27:1475–80. https://doi.org/10.1089/THY.2017.0365.

Article  PubMed  Google Scholar 

Smith TJ, Hegedüs L, Lesser I, et al. How patients experience thyroid eye disease. Front Endocrinol (Lausanne). 2023;14:1283374. https://doi.org/10.3389/FENDO.2023.1283374/FULL.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Padnick-Silver L, Francis-Sedlak M, et al. Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States. Endocr Pract. 2022;28:842–6. https://doi.org/10.1016/J.EPRAC.2022.06.003.

Article  PubMed  Google Scholar 

Rundle FF. Management of exophthalmos and related ocular changes in Graves’ disease. Metabolism. 1957;6:36–48.

PubMed  CAS  Google Scholar 

Ugradar S, Rootman DB. Noninflammatory thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2019;35:461–4. https://doi.org/10.1097/IOP.0000000000001087.

Article  PubMed  Google Scholar 

Uddin JM, Rubinstein T, Hamed-Azzam S. Phenotypes of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34:S28-33.

Article  PubMed  Google Scholar 

Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Basingstoke). 2020. https://doi.org/10.1038/s41433-020-01297-w.

Article  Google Scholar 

Ugradar S, Douglas R. Comparison of acute and chronic thyroid eye disease: emergence of a molecular signature. Am Acad Ophthalmol. 2022.

Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639–44. https://doi.org/10.1136/bjo.73.8.639.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43-67. https://doi.org/10.1530/EJE-21-0479.

Article  PubMed  CAS  Google Scholar 

Werner SC. Modification of the classification of the eye changes of Graves’ disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44:203–4. https://doi.org/10.1210/JCEM-44-1-203.

Article  PubMed  CAS  Google Scholar 

Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001;54:391–8. https://doi.org/10.1046/J.1365-2265.2001.01241.X.

Article  PubMed  CAS  Google Scholar 

Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773–9. https://doi.org/10.1136/BJO.82.7.773.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves’ ophthalmopathy. Clin Exp Immunol. 1989;75:222–7.

PubMed  PubMed Central  CAS  Google Scholar 

Van Steensel L, Paridaens D, Van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in graves’ ophthalmopathy. J Clin Endocrinol Metab. 2012. https://doi.org/10.1210/jc.2011-2697.

Article  PubMed  Google Scholar 

Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95:430–8. https://doi.org/10.1210/jc.2009-1614.

Article  PubMed  CAS  Google Scholar 

Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178:3281–7. https://doi.org/10.4049/JIMMUNOL.178.5.3281.

Article  PubMed  CAS  Google Scholar 

Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008. https://doi.org/10.4049/jimmunol.181.8.5768.

Article  PubMed  Google Scholar 

Li B, Smith TJ. Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts. J Clin Endocrinol Metab. 2014;99:E625–33. https://doi.org/10.1210/jc.2013-3977.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Raychaudhuri N, Fernando R, Smith TJ. Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0075100.

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Atkins SJ, Fernando R, et al. CD34: orbital fibroblasts from patients with thyroid-associated ophthalmopathy modulate TNF-α expression in CD34 + fibroblasts and fibrocytes. Invest Ophthalmol Vis Sci. 2018;59:2615–22. https://doi.org/10.1167/iovs.18-23951.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hong KM, Belperio JA, Keane MP, et al. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-β and peroxisome proliferator-activated receptor. J Biol Chem. 2007. https://doi.org/10.1074/jbc.M703597200.

Article  PubMed  Google Scholar 

Furmaniak J, Sanders J, Young S, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1–70). Auto Immun Highlights. 2012. https://doi.org/10.1007/s13317-011-0025-9.

Article  PubMed  PubMed Central  Google Scholar 

Bothun ED, Scheurer RA, Harrison AR, et al. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543–51.